Juno Pharmaceuticals Corp. (“Juno”), a Canadian specialty generics pharmaceuticals company, announced that it has received a strategic growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare growth equity firm.

The proceeds will support Juno in expanding its complex and high-value generic and biosimilar portfolio and accelerating growth.

Aird & Berlis LLP acted as legal counsel for Juno Pharmaceuticals Corp. with a team including Richard Epstein, Lorway Gosse, Aaron Bains (Corporate/Commercial) and Francesco Gucciardo (Tax).

Sheppard, Mullin, Richter & Hampton LLP acted as legal counsel for Signet Healthcare Partners.